Amino acid derivative and bromoacetyl modified peptides
CA 2111465 A1 · Owner: Inman, John K. · Inventors: Inman, John K.; Robey, Frank A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A new amino acid derivative, N.alpha.-tert-butoxycarbonyl-N.epsilon.-(N-bromoacetyl-.beta.-alanyl)-L-lysine (BBAL) has been synthes-, ized as a reagent to be used in solid-phase peptide synthesis for introducing a side-chain bromoacetyl group at any desired position in a peptide sequence. The bromoacetyl group subsequently serves as a sulfhydryl-selective cross-liking function for the preparation of cyclic peptides, peptide conjugates and polymers. BBAL residues are stable to final HF deprotection/cleavage. BBAL peptides can be directly coupled to other molecules or surfaces which possess free sulfhydryl groups by forming stable thioether linkages. Peptides containing both BBAL and cysteine …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 10, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 10, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 10, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.